Managing osteoporosis in postmenopausal women

American Journal of Health-System Pharmacy

Volumn 67, Issue SUPPL. 3, 2010, Pages

  Vondracek, Sheryl F ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Antibodies; Bisphosphonates; Calcitonin salmon; Calcium; Denosumab; Estrogen agonist antagonists; Fractures; Hormones; Minerals; Osteoporosis; Pharmacists, hospital; Postmenopause; Raloxifene; Teriparatide; Vitamin D; Vitamins; Women

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CALCIUM; CALCIUM CARBONATE; CITRATE CALCIUM; COLECALCIFEROL; DENOSUMAB; ERGOCALCIFEROL; HYDROCHLOROTHIAZIDE; HYPNOTIC AGENT; IBANDRONIC ACID; LANSOPRAZOLE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARACETAMOL; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; SALCATONIN; SEDATIVE AGENT; UNINDEXED DRUG; VITAMIN D; VITAMIN K GROUP; ZOLEDRONIC ACID; ALCOHOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; NEUROLEPTIC AGENT; OPIATE; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ALCOHOL CONSUMPTION; BEVERAGE; BONE MASS; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; CALCIUM ABSORPTION; CALCIUM INTAKE; CALCIUM URINE LEVEL; CIGARETTE SMOKING; CONFERENCE PAPER; COUNSELING; DIET; DIET SUPPLEMENTATION; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG LABELING; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; EXERCISE; FALLING; FRAGILITY FRACTURE; GASTROESOPHAGEAL REFLUX; HEALTH CARE SYSTEM; HOME SAFETY; HUMAN; HYPERTENSION; JAW OSTEONECROSIS; LIFESTYLE; MALABSORPTION; OSTEOARTHRITIS; OSTEOLYSIS; PHARMACIST; PHYSICAL ACTIVITY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SMOKING CESSATION; STOMACH ACID; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION; VENOUS THROMBOEMBOLISM; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN INTAKE; WEIGHT BEARING; WRIST FRACTURE; ABDOMINAL PAIN; AGED; ARTHRALGIA; BLOATING; CASE REPORT; CELLULITIS; CONSTIPATION; DEEP VEIN THROMBOSIS; DIETARY INTAKE; DIZZINESS; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRY NOSE; DYSPEPSIA; ECZEMA; EPISTAXIS; FEMALE; FLATULENCE; FRACTURE; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HOT FLUSH; HYPERCALCEMIA; HYSTERECTOMY; LEG CRAMP; LIFESTYLE MODIFICATION; NAUSEA; NOSE IRRITATION; OSTEOSARCOMA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; RESISTANCE TRAINING; SALMON; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

EID: 77950610348     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp100076     Document Type: Conference Paper

References (55)

1. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008. www.nof.org/professionals/Clinicians-Guide.htm (accessed 2009 Dec 2).
2. O'Connell MB, Vondracek SF. Osteoporosis and other metabolic bone diseases. In: DiPiro JT, Talbert RL, Yee GC et al., eds. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York, NY: McGraw-Hill; 2008:1483-1504
3. U.S. Department of Health and Human Services. 2008 Physical activity guidelines for Americans. www.health.gov/paguidelines/ (accessed 2009 Dec 7).
4. U.S. Department of Agriculture. Dietary guidelines for Americans 2005. www.health.gov/dietaryguidelines/dga2005/document/pdf/DGA2005.pdf (accessed 2009 Dec 7).
5. Hallström H, Wolk A, Glynn A et al. Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women. Osteoporosis Int. 2006; 17:1055-1064
6. National Institutes of Health, Office of Dietary Supplements. Dietary supplement fact sheet: calcium. http://ods.od.nih.gov/factsheets/calcium.asp (accessed 2009 Dec 7).
7. Kanis JA, Johnell O, Oden A et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005; 16:155-162
8. Centers for Disease Control and Prevention. Falls - older adult. What YOU can do to prevent falls (brochure). www.cdc.gov/HomeandRecreationalSafety/pubs/ English/brochure-Eng-desktop-a.pdf (accessed 2009 Dec 7).
9. Centers for Disease Control and Prevention. Check for safety: a home fall prevention checklist for older adults. www.cdc.gov/ncipc/pub-res/toolkit/Falls- ToolKit/DesktopPDF/English/booklet-Eng-desktop.pdf (accessed 2009 Dec 7).
10. National Osteoporosis Foundation. What you should know about calcium. www.nof.org/prevention/calcium2.htm (accessed 2009 Dec 7).
11. U.S. Food and Drug Administration. How to understand and use the nutrition facts label. www.cfsan.fda.gov/dms/foodlab.html (accessed 2009 Dec 7).
12. U.S. Pharmacopeia. The USP dietary supplement verification program. www.usp.org/USPVerified/dietarySupplements/ (accessed 2009 Dec 7).
13. National Osteoporosis Foundation. Prevention: vitamin D. www.nof.org/prevention/vitaminD.htm (accessed 2009 Dec 7).
14. 3 intake for the elderly. J Nutr. 2006; 136:1123-1125
15. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357:266-281
16. Holick MF, Siris ES, Binkley N et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005; 90:3215-3224 (Pubitemid 41014278)
17. Bone health and osteoporosis: a report of the Surgeon General. Chapter 2: the basics of bone in health and disease. www.surgeongeneral.gov/library/ bonehealth/chapter-2.html (accessed 2009 Dec 7).
18. Fosamax package insert. Whitehouse Station, NJ: Merck & Co., Inc; 2009 Jun.
19. Fosamax Plus D package insert. Whitehouse Station, NJ: Merck & Co., Inc; 2009 Jun.
20. Boniva tablets package insert. Nutley, NJ: Roche Laboratories, Inc.; 2008 Nov.
21. Boniva injection package insert. Nutley, NJ; Roche Laboratories, Inc.; 2009 Jul.
22. Actonel package insert. Cincinnati, OH: Procter & Gamble Pharmaceuticals, Inc.; 2009 Aug.
23. Reclast package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009 May.
24. Grey A, Bolland MJ, Wattie D et al. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab. 2009; 94:538-544
25. Evista package insert. Indianapolis, IN: Eli Lilly and Company; 2008 Oct.
26. Miacalcin nasal spray package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2006 Jun.
27. Cummings SR, San Martin J, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361:756-765
28. Forteo package insert. Indianapolis, IN: Eli Lilly and Company; 2009 Jul.
29. Kavanagh KL, Guo K, Dunford JE et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA. 2006; 103:7829-7834
30. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83:1032-1045
31. Reid IR. Menopause. In: Rosen CJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th ed. Washington, DC: American Society for Bone and Mineral Research; 2008:95-97.
32. McEvoy GK, ed. Raloxifene hydrochloride. In: AHFS drug information 2009. Bethesda, MD: American Society of Health-System Pharmacists; 2009:3178-3183
33. McEvoy GK, ed. Calcitonin. In: AHFS drug Information 2009. Bethesda, MD: American Society of Health-System Pharmacists; 2009:3286-3289
34. Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep. 2009; 7:18-22.
35. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007; 40:1434-1446
36. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348:1535-1541
37. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA. 1999; 282:1344-1352
38. Chesnut CH 3rd, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19:1241-1249
39. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356:1809-1822.
40. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA. 1999; 282:637-645
41. Chesnut CH 3rd, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000; 109:267-276
42. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344;1434-1441
43. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001; 344:333-340 (Pubitemid 32107641)
44. Confavreux C, Canoui-Poitrine F, Tainturier V et al. Persistence at 1 year of several oral antiosteoporotic drugs as a function of dosing frequency: a prospective study. J Bone Miner Res. 2009; 24(Suppl 1): abstract A09002577. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid= f6001643-3a8e-4efd-84bd-88ea9cd56ec1 (accessed 2009 Dec 8).
45. International Osteoporosis Foundation. The adherence gap: why osteoporosis patients don't continue with treatment. www.iofbonehealth.org/ publications/the-adherence-gap.html (accessed 2009 Nov 24).
46. Siris ES, Selby PL, Saag KG et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009; 122(Suppl 2):S3-S13.
47. Traveling with Forteo. www.forteo.com/secure/user/traveling.jsp (accessed 2010 Jan 9).
48. Zometa package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009 Oct.
49. Khan AA, Sándor GK, Dore E et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2009; 36:478-490
50. Bone HG, Bolognese MA, Yuen CK et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93:2149-2157 (Pubitemid 351831529)
51. Amgen provides update on status of Prolia (denosumab) biologics application (BLA) submitted to the U.S. Food and Drug Administration. Oct 19, 2009. www.psa-rising/wiredbird/amgen-denosumab-101909.htm (accessed 2010 Feb 4).
52. American Society of Health-System Pharmacists. ASHP therapeutic position statement on the prevention and treatment of osteoporosis in adults. Am J Health-Syst Pharm. 2008; 65:343-357
53. FDA classified Prolia (denosumab) complete response submission and targets action date. February 19, 2010. www.amgen.com/media/media-pr-detail.jsp? releaseod=1393314 (accessed 2010 Feb 23).
54. Hodgson SR, Watts NB, Bilezikian JP et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003; 9:544-564
55. World Health Organization. FRAX WHO fracture risk assessment tool: US (black). http://www.shef.ac.uk/FRAX/tool.jsp?locationValue=1 (accessed 2009 Dec 2).